Logo image of NANO.PA

NANOBIOTIX (NANO.PA) Stock Fundamental Analysis

EPA:NANO - Euronext Paris - Matif - FR0011341205 - Common Stock - Currency: EUR

3.314  -0.12 (-3.38%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NANO. NANO was compared to 69 industry peers in the Biotechnology industry. Both the profitability and financial health of NANO have multiple concerns. NANO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NANO had negative earnings in the past year.
NANO had a negative operating cash flow in the past year.
NANO had negative earnings in each of the past 5 years.
In the past 5 years NANO always reported negative operating cash flow.
NANO.PA Yearly Net Income VS EBIT VS OCF VS FCFNANO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

NANO has a Return On Assets (-38.62%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -38.62%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NANO.PA Yearly ROA, ROE, ROICNANO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K 2K 2.5K

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NANO.PA Yearly Profit, Operating, Gross MarginsNANO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100K -200K -300K -400K -500K

More info and screens

1

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NANO has more shares outstanding
The number of shares outstanding for NANO has been increased compared to 5 years ago.
NANO has a better debt/assets ratio than last year.
NANO.PA Yearly Shares OutstandingNANO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
NANO.PA Yearly Total Debt VS Total AssetsNANO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.74, we must say that NANO is in the distress zone and has some risk of bankruptcy.
NANO's Altman-Z score of -4.74 is on the low side compared to the rest of the industry. NANO is outperformed by 69.57% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.74
ROIC/WACCN/A
WACC9.16%
NANO.PA Yearly LT Debt VS Equity VS FCFNANO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

NANO has a Current Ratio of 1.42. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.42, NANO is not doing good in the industry: 65.22% of the companies in the same industry are doing better.
NANO has a Quick Ratio of 1.42. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
NANO has a worse Quick ratio (1.42) than 62.32% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.42
NANO.PA Yearly Current Assets VS Current LiabilitesNANO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

NANO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.64%, which is quite impressive.
The Revenue has been growing by 203.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y203.88%
Sales Q2Q%182.08%

3.2 Future

Based on estimates for the next years, NANO will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
The Revenue is expected to grow by 15.35% on average over the next years. This is quite good.
EPS Next Y1.31%
EPS Next 2Y1.7%
EPS Next 3Y12.83%
EPS Next 5Y6.46%
Revenue Next Year-32.55%
Revenue Next 2Y-24.94%
Revenue Next 3Y28.64%
Revenue Next 5Y15.35%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NANO.PA Yearly Revenue VS EstimatesNANO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
NANO.PA Yearly EPS VS EstimatesNANO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NANO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NANO.PA Price Earnings VS Forward Price EarningsNANO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NANO.PA Per share dataNANO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as NANO's earnings are expected to grow with 12.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.7%
EPS Next 3Y12.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NANO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX

EPA:NANO (3/26/2025, 4:59:30 PM)

3.314

-0.12 (-3.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2024-11-10
Earnings (Next)04-23 2025-04-23/amc
Inst Owners24.66%
Inst Owner ChangeN/A
Ins Owners0.3%
Ins Owner ChangeN/A
Market Cap157.10M
Analysts85.45
Price Target11.02 (232.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.76
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.3%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.35%
Cap/Sales 1.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.42
Altman-Z -4.74
F-Score6
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)14.47%
Cap/Depr(5y)26.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.5%
EPS Next Y1.31%
EPS Next 2Y1.7%
EPS Next 3Y12.83%
EPS Next 5Y6.46%
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y203.88%
Sales Q2Q%182.08%
Revenue Next Year-32.55%
Revenue Next 2Y-24.94%
Revenue Next 3Y28.64%
Revenue Next 5Y15.35%
EBIT growth 1Y45.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-172.31%
EBIT Next 3Y-15.13%
EBIT Next 5Y-22.73%
FCF growth 1Y95.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.79%
OCF growth 3YN/A
OCF growth 5YN/A